Early results from new PD-1 targeted immune therapy

Share :
Published: 2 Jun 2012
Views: 4310
Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, USA

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Suzanne Topalian presented results from an early-stage study showing treatment with the investigational drug BMS-936558.


The drug caused tumour shrinkage in up to a quarter of patients with advanced melanoma, kidney and non-small cell lung (NSCLC) cancers. 


ecancerNews Coverage